Repligen Co. (NASDAQ:RGEN) Shares Sold by Riverbridge Partners LLC

Riverbridge Partners LLC trimmed its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 409,333 shares of the biotechnology company's stock after selling 8,423 shares during the quarter. Riverbridge Partners LLC owned about 0.73% of Repligen worth $73,598,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Fortis Capital Advisors LLC grew its holdings in Repligen by 32.7% in the 1st quarter. Fortis Capital Advisors LLC now owns 272 shares of the biotechnology company's stock worth $46,000 after buying an additional 67 shares in the last quarter. Signaturefd LLC grew its holdings in Repligen by 44.1% in the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company's stock worth $45,000 after buying an additional 86 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in Repligen by 14.8% during the 3rd quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company's stock valued at $107,000 after purchasing an additional 87 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Repligen by 3.2% during the 3rd quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company's stock valued at $509,000 after purchasing an additional 100 shares in the last quarter. Finally, State of Michigan Retirement System boosted its stake in Repligen by 0.8% during the 4th quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $2,239,000 after purchasing an additional 100 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Repligen news, COO James Bylund sold 4,373 shares of the firm's stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Repligen news, COO James Bylund sold 4,373 shares of the firm's stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares of the company's stock, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock worth $5,039,532 over the last quarter. Company insiders own 1.10% of the company's stock.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded down $4.38 during midday trading on Thursday, hitting $172.94. The company's stock had a trading volume of 429,751 shares, compared to its average volume of 543,264. The stock has a market capitalization of $9.64 billion, a price-to-earnings ratio of 240.20, a PEG ratio of 5.83 and a beta of 1.02. The stock's 50 day simple moving average is $194.24 and its 200 day simple moving average is $172.50. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts' consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The business had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. During the same period last year, the business earned $0.68 earnings per share. The firm's revenue for the quarter was down 16.6% compared to the same quarter last year. As a group, research analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current year.

Analysts Set New Price Targets

RGEN has been the subject of several research reports. KeyCorp raised their price objective on Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. increased their target price on Repligen from $170.00 to $210.00 and gave the company an "overweight" rating in a report on Wednesday, December 20th. Finally, Stifel Nicolaus increased their target price on Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $196.70.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.